The American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, presented exciting updates in urothelial carcinoma. Here, Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, discusses data for the antibody-drug conjugate enfortumab vedotin, which targets Nectin-4 (EV-101; NCT02091999).
Enfortumab vedotin: targeting bladder cancer
